Canopy Growth Faces Scrutiny on Turnaround Sustainability

Narrowed Losses Mask Revenue Decline

Canopy Growth cut its quarterly net loss by 47% year-over-year to CA$47 million in fiscal Q1 2027, but revenue fell 8% to CA$62 million. The loss reduction stems primarily from cost-cutting measures initiated in fiscal 2026, including facility closures in Smiths Falls, Ontario, and workforce reductions totaling approximately 800 employees. According to the company's MD&A filed July 20, 2026, adjusted EBITDA improved to negative CA$12 million from negative CA$31 million in Q1 2026.

Revenue fell on continued market-share erosion in Canada. Recreational cannabis sales dropped 11% to CA$41 million. Medical cannabis revenue held flat at CA$21 million, buoyed by international markets including Germany and Australia.

Cash Position and Burn Rate Raise Capital Questions

Canopy Growth held CA$198 million in cash and equivalents as of June 30, 2026, with a quarterly cash-burn rate of approximately CA$35 million. At that rate, the company has roughly 5.6 quarters of runway before requiring additional financing. The company's July 20 earnings call disclosed no immediate plans for equity raises, but CFO Judy Hong said Canopy is "evaluating all strategic options to optimize the balance sheet."

Debt stands at CA$412 million. That includes CA$297 million in convertible senior notes due December 2027. The notes carry a 4.25% coupon and convert at US$13.00 per share—a conversion price 620% above the July 20 closing price of US$1.79.

Regulatory Tailwinds and Operational Risks

Potential U.S. cannabis rescheduling under the DEA's pending rule could unlock cross-border opportunities, but Canopy's U.S. operational footprint remains limited. The company divested its U.S. CBD and hemp assets in fiscal 2025 and currently holds no direct U.S. cannabis licenses. CEO David Klein said on the July 20 call that Canopy is "monitoring the U.S. regulatory environment closely" but provided no timeline for re-entry.

In Canada, Canopy faces intensifying price compression. The national average wholesale price for dried flower fell to CA$3.12 per gram in Q2 2026, down from CA$4.18 per gram in Q2 2025, according to Health Canada data. Canopy's gross margin contracted to 18% in Q1 2027 from 23% in Q1 2026. For context on Canopy's broader strategic pivot, see the CannIntel topic hub on Canopy Growth's turnaround efforts.

We'll be watching whether Canopy can stabilize revenue before its December 2027 debt maturity—and whether management signals capital-raising plans before the cash runway narrows further.